RxDoctor Payments DataLook up a doctor →

Kenneth Burnham, MD

Advanced Heart Failure and Transplant Cardiology · Mobile, ALNPI 1164462321

Payments from drug & device makers

$445,713in general payments, 2019–2025

Across 792 payments — averaging $562.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$108K
  • Novartis$68K
  • Boehringer Ingelheim$62K
  • AstraZeneca$61K
  • Pfizer$60K
  • Lexicon Pharmaceuticals, Inc.$49K
  • plus $37K from 27 others

What the payments were for

  • Consulting fees$11,5153%
  • Speaking & faculty fees$390,35088%
  • Travel & lodging$24,9206%
  • Food & beverage$18,6134%
  • Education$3160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$287,019
Medicare patients
952
Services billed
3,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan1,133$1,192,899
Orenitram ErTreprostinil Diolamine30$1,158,196
VyndamaxTafamidis38$1,111,915
AdempasRiociguat75$1,084,842
Tyvaso DpiTreprostinil39$938,730
EliquisApixaban972$894,623
CamzyosMavacamten82$664,305
OpsumitMacitentan44$583,455
FarxigaDapagliflozin Propanediol708$564,323
JardianceEmpagliflozin295$291,473
LetairisAmbrisentan15$244,089
Ambrisentan48$191,625
XareltoRivaroxaban135$156,731
FuroscixFurosemide11$55,474
Repatha SureclickEvolocumab49$50,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$60,297$2,006,5381,010 claims
NovartisEntresto$68,182$1,192,8991,133 claims
BayerAdempas$5,452$1,084,84275 claims
E.r. Squibb & Sons, L.L.C.Camzyos$108,480$664,30582 claims
AstraZenecaFarxiga, Brilinta$60,968$584,252747 claims
Actelion Pharmaceuticals US, Inc.Opsumit$5,226$583,45544 claims
Boehringer IngelheimJardiance$62,270$291,473295 claims
Johnson & JohnsonXarelto$352$156,731135 claims
Scpharmaceuticals Inc.Furoscix$503$55,47411 claims
MerckVerquvo$292$35,96342 claims
Novo NordiskWegovy$34$23,25718 claims
AmgenCorlanor$229$15,80625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Alabamaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →